How do you select between imlunestrant +/- abemaciclib and elacestrant for those with an ESR1 mutation and progressed on AI and CDK 4/6 inhibitor for patients with metastatic ER+/HER2- breast cancer?  

My choice of oral SERD to use in this setting would be based on side effect profile and ease of administration, as both are approved for use after progression on 1st-line ET. Based on information from the phase III trials, EMERALD and EMBER-3, and in the absence of a head-to-head comparison, imlun...